{"id":39307,"date":"2021-01-28T09:16:55","date_gmt":"2021-01-28T09:16:55","guid":{"rendered":"https:\/\/setterwalls.se\/case\/setterwalls-has-advised-alligator-bioscience-in-connection-with-over-subscribed-rights-issue\/"},"modified":"2022-02-14T13:44:10","modified_gmt":"2022-02-14T13:44:10","slug":"setterwalls-has-advised-alligator-bioscience-in-connection-with-over-subscribed-rights-issue","status":"publish","type":"assignments","link":"https:\/\/setterwalls.se\/en\/case\/setterwalls-has-advised-alligator-bioscience-in-connection-with-over-subscribed-rights-issue\/","title":{"rendered":"Setterwalls has advised Alligator Bioscience in connection with over-subscribed rights issue"},"content":{"rendered":"<p><strong>Setterwalls has advised Alligator Bioscience AB (\u201cAlligator\u201d), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 86 million. The rights issue was subscribed to approximately 163 per cent.<\/strong><\/p>\n<p>Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator\u2019s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator\u2019s shares are listed on Nasdaq Stockholm since 2016. The company is headquartered in Lund, Sweden<\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Setterwalls has advised Alligator Bioscience AB (\u201cAlligator\u201d), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 86 million. The rights issue was subscribed to approximately 163 per cent.<\/strong><\/p>\n<p>Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator\u2019s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator\u2019s shares are listed on Nasdaq Stockholm since 2016. The company is headquartered in Lund, Sweden<\/p>\n","protected":false},"author":1,"featured_media":34109,"template":"","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":""},"class_list":["post-39307","assignments","type-assignments","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments\/39307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments"}],"about":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/types\/assignments"}],"author":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media\/34109"}],"wp:attachment":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media?parent=39307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}